Johnson & Johnson (JNJ)vsRepro Med Systems Inc (KRMD)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
KRMD
Repro Med Systems Inc
$3.99
+0.50%
HEALTHCARE · Cap: $188.84M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 234201% more annual revenue ($96.36B vs $41.13M). JNJ leads profitability with a 21.8% profit margin vs -6.4%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
KRMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
-71.4%
Fair Value
$2.66
Current Price
$3.99
$1.33 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 23.3% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Trading at 10.8x book value
Smaller company, higher risk/reward
ROE of -15.6% — below average capital efficiency
Earnings declined 66.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : KRMD
The strongest argument for KRMD centers on Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : KRMD
The primary concerns for KRMD are Price/Book, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while KRMD is a growth play — different risk/reward profiles.
KRMD carries more volatility with a beta of 0.54 — expect wider price swings.
KRMD is growing revenue faster at 23.3% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 24/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Repro Med Systems Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?